Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2018

Open Access 01-12-2018 | Research article

Low-dose trofosfamide plus rituximab is an effective and safe treatment for diffuse large B-cell lymphoma of the elderly: a single center experience

Authors: Roland Christian Schelker, Wolfgang Herr, Albrecht Reichle, Martin Vogelhuber

Published in: BMC Cancer | Issue 1/2018

Login to get access

Abstract

Background

Rituximab plus combination chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is broadly accepted as standard for the treatment of diffuse large B-cell lymphoma (DLBCL). Nevertheless, there is sparsely data concerning the management of elderly patients.

Methods

We performed a retrospective study of treatment with rituximab and low-dose trofosfamide in elderly patients (≥ 75 years) with DLBCL who were not suitable for R-CHOP or R-CHOP-like regimens or who did not consent to aggressive treatment. The choice regarding the qualification for R-CHOP or R-CHOP-like regimen was left to the estimation of the treating physicians.

Results

Eleven patients with a median age of 83 years (range, 75–90 years) were included. The age-adjusted international prognostic index was low risk in one patient, low-intermediate in four patients, high-intermediate in three patients, and high risk in 3 patients. All patients were evaluable for response. Five patients (45%) achieved a complete response, three (27%) a partial response, one (9%) stable disease, and two (18%) progressive disease. The estimated 1-yr overall survival was 54.5%, and the estimated 1-yr progression-free survival 45.5%, however, three patients (27%) were alive without evidence of disease at 16–20 months from start of treatment. Main toxicity was leukopenia (36% grade III or IV), whereas grade III/IV non-hematological adverse events did not occur.

Conclusions

Due to its potency and low toxicity, trofosfamide/rituximab might represent an alternative therapy for DLBCL of elderly patients not suitable for R-CHOP. This observation, however, should be confirmed in a larger patient population within a prospective clinical trial.
Literature
1.
Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood. 2006;107:265–76.CrossRefPubMedCentralPubMed
2.
d’Amore F, Brincker H, Christensen BE, Thorling K, Pedersen M, Nielsen JL, et al. Non-Hodgkin’s lymphoma in the elderly. A study of 602 patients aged 70 or older from a Danish population-based registry. The Danish LYEO-Study Group. Ann Oncol. 1992;3(5):379–86.CrossRefPubMed
3.
Hoerni B, Sotto JJ, Eghbali H, Sotto MF, Noerni-Simon G, Pegourié B. Non-Hodgkin’s malignant lymphomas in patients older than 80: 70 cases. Cancer. 1988;61:2057–9.CrossRefPubMed
4.
Bairey O, Benjamini O, Blickstein D, Elis A, Ruchlemer R. Non-Hodgkin’s lymphoma in patients 80 years of age or older. Ann Oncol. 2006;17:928–34.CrossRefPubMed
5.
Thieblemont C, Grossoeuvre A, Houot R, Broussais-Guillaumont F, Salles G, Traullé C, et al. Non-Hodgkin’s lymphoma in very elderly patients over 80 years. A descriptive analysis of clinical presentation and outcome. Ann Oncol. 2008;19:774–9.CrossRefPubMed
6.
Italiano A, Jardin F, Peyrade F, Saudes L, Tilly H, Thyss A. Adapted CHOP plus rituximab in non-Hodgkin’s lymphoma in patients over 80 years old. Haematologica. 2005;90:1281–3.PubMed
7.
Klapper W, Kreuz M, Kohler CW, Burkhardt B, Szczepanowski M, Salaverria I, et al. Patient age at diagnosis is associated with the molecular characteristics of diffuse large B-cell lymphoma. Blood. 2012;119:1882–7.CrossRefPubMed
8.
Armitage JO, Potter JF. Aggressive chemotherapy for diffuse histiocytic lymphoma in the elderly: increased complications with advancing age. J Am Geriatr Scc. 1984;32:269–73.CrossRef
9.
Bastion Y, Blay JY, Divine M, Brice P, Bordessoule D, Sebban C, et al. Elderly patients with aggressive non-Hodgkin’s lymphoma: disease presentation, response to treatment, and survival – a group d’étude des Lymphomes de l’Adulte study on 453 patients older than 69 years. J Clin Oncol. 1997;15:2945–53.CrossRefPubMed
10.
Bessell EM, Burton A, Haynes AP, Glaholm J, Child JA, Cullen MH, et al. A randomized multicenter trial of modified CHOP versus MCOP in patients aged 65 years and over with aggressive non-Hodgkin’s lymphoma. Ann Oncol. 2003;14:258–67.CrossRefPubMed
11.
Osby E, Hagberg H, Kvaloy S, Teerenhovi L, Anderson H, Cavallin-Stahl E, et al. CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: results of a Nordic lymphoma group randomized trial. Blood. 2003;101:3840–8.CrossRefPubMed
12.
Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235–42.CrossRefPubMed
13.
Feugier P, Van Hoof A, Sebban C, Dolal-Celigny P, Bouabdallah R, Fermé C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol. 2005;23(18):4117–26.CrossRefPubMed
14.
Coiffier B, Thieblemont C, van den Neste E, Lepeu G, Plantier I, Castaigne S, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d’Etudes des Lymphomes de l’Adulte. Blood. 2010;116:2040–5.CrossRefPubMedCentralPubMed
15.
Pfreundschuh M, Schubert J, Ziepert M, Schmits R, Mohren M, Lengfelder E, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a 17onrandomi controlled trial (RICOVER-60). Lancet Oncol. 2008;9:105–16.CrossRefPubMed
16.
Habermann TM, Weller EA, Morrison VA, Gascoyne RD, Cassileth PA, Cohn JB, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol. 2006;24:3121–7.CrossRefPubMed
17.
Visani G, Ferrara F, Alesiani F, Ronconi S, Catarini M, D’adamo F, et al. R-COMP 21 for frail elderly patients with aggressive B-cell non-Hodgkin lymphoma: a pilot study. Leuk Lymphoma. 2008;49:1081–6.CrossRefPubMed
18.
Corazzelli G, Frigeri F, Arcamone M, Lucania A, Rosariavilla M, Morelli E, et al. Biweekly rituximab, cyclophosphamide, vincristine, non-pegylated liposome-encapsulated doxorubicin and prednisone (R-COMP-14) in elderly patients with poor-risk diffuse large B-cell lymphoma and moderate to high ‘life threat’ impact cardiopathy. Brit J Haematol. 2011;154:579–89.CrossRef
19.
Ricciuti G, Finolezzi e LS, Ranucci E, Federico M, Di Nicola M, et al. Combination of rituximab and nonpegylated liposomal doxorubicin (R-NPLD) as front-line therapy for aggressive non-Hodgkin lymphoma (NHL) in patients 80 years of age or older: a single-center retrospective study. Hematol Oncol. 2017. https://​doi.​org/​10.​1002/​hon.​2386.CrossRefPubMed
20.
Zhou D, Li L, Bao C, Zhu J, Zhu L, Yang X, et al. Replacement of conventional doxorubicin by pegylated liposomal doxorubicin in standard RCHOP chemotherapy for elderly diffuse large B-cell lymphoma: a retrospective study in China. Int J Clin Exp Med. 2015;8(12):22497–502.PubMedPubMedCentral
21.
Peyrade F, Jardin F, Thieblemont C, Thyss A, Emile JF, Castaigne S, et al. Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a 18onrandomiz, single-arm, phase 2 trial. Lancet Oncol. 2011;12:460–8.CrossRefPubMed
22.
Musolino A, Boggiani D, Panebianco M, Fontana E, Zanoni D, Bozzetti C, et al. Activity and safety of dose-adjusted infusional cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy with rituximab in very elderly patients with poor-prognostic untreated diffuse large B-cell non-Hodgkin lymphoma. Cancer. 2011;117:964–73.CrossRefPubMed
23.
Hainsworth JD, Flinn IW, Spigel DR, Clark BL, Griner PL, Vazquez ER, et al. Brief-duration rituximab/chemotherapy followed by maintenance rituximab in patients with diffuse large B-cell lymphoma who are poor candidates for R-CHOP chemotherapy: a phase II trial of the Sarah Cannon oncology research consortium. Clin Lymph Myel Leuk. 2010;10:44–50.CrossRef
24.
Fields FA, Townsend W, Webb A, Counsell N, Pocock C, Smith P, et al. De novo treatment of diffuse large B-cell lymphoma with rituximab, cyclophosphamide, vincristine, gemcitabine, and prednisolone in patients with cardiac comorbidity: a United Kingdom National Cancer Research Institute project. J Clin Oncol. 2014;32:282–7.CrossRefPubMed
25.
Peyrade F, Bologna S, Delwail V, Emile JF, Pascal L, Fermé C, et al. Combination of ofatumumab and reduced-dose CHOP for diffuse large B-cell lymphomas in patients aged 80 years or older: an open-label, multicenter, single-arm, phase 2 trial from the LYSA group. Lancet Haematol. 2017;4(1):e46–55.CrossRefPubMed
26.
Chihara D, Westin JR, Oki Y, Ahmed MA, Do B, Fayad LE, et al. Management strategies and outcomes for very elderly patients with diffuse large B-cell lymphoma. Cancer. 2016;122(20):3145–51.CrossRefPubMed
27.
Wist E, Risberg T. Trofosfamide in non-Hodgkin’s lymphoma. A phase II study. Acta Oncol. 1991;30(7):819–21.CrossRefPubMed
28.
Salminen E, Nikkanen V, Lindholm L. Palliative chemotherapy in non-Hodgkin’s lymphoma. Oncology. 1997;54(2):108–11.CrossRefPubMed
29.
Helsing MD. Trofosfamide as a salvage treatment with low toxicity in malignant lymphoma. A phase II study. Eur J Cancer. 1997;33(3):500–2.CrossRefPubMed
30.
Wiedemann GJ, Zschaber R, Hegewisch-Becker S, Reichardt P, Weber K, Uthgenannt D, et al. Two oral trofosfamide schedules in elderly patients with refractory non-Hodgkin’s lymphoma. Onkologie. 1999;22:134–8.
31.
Andersson PO, Braide I, Nilsson-Ehle H. Trofosfamide as a salvage therapy for anaplastic large cell lymphoma relapsing after high dose chemotherapy. Leuk Lymphoma. 2002;43:2351–3.CrossRefPubMed
32.
Hart C, Vogelhuber M, Wolff D, Klobuch S, Ghibelli L, Foell J, et al. Anakoinosis: communicative reprogramming of tumor systems – for rescuing from chemorefractory neoplasia. Cancer Microenviron. 2015;8(2):75–92.CrossRefPubMedCentralPubMed
33.
Aigner B, Richtig E, Becker JC, Lingitz H, Marterer R, Niederkorn A, et al. Partial response of metastatic mucosal melanoma after palliative chemotherapy with trofosfamide: a case report. J Clin Oncol. 2013;31(2):e31–2.CrossRefPubMed
34.
Brinker A, Kisro J, Letsch C, Brüggemann SK, Wagner T, et al. New insights into the pharmacokinetics of trofosfamide. Int J Clin Pharmacol Ther. 2002;40:376–81.CrossRefPubMed
35.
Lindemann H, Harbers E. Interaction of three alkylating drugs, cyclophosphamide, ifosfamide and trofosfamide with DNA and DNA-constituents in vitro. Arzneimittelforschung. 1980;30:2075–80.PubMed
36.
Klink T, Marxsen JH, Wagner T. Trofosfamide equally inhibits endothelial and tumor cell growth. Onkologie. 2002;25(Suppl 4):24 (A85).
37.
Hempel G, Krumpelmann S, May-Manske A, Hohenlöchter B, Blaschke G, Jürgens H, et al. Pharmacokinetics of trofosfamide and its dechloroethyl-metabolites. Cancer Chemother Pharmacol. 1997;40:45–50.CrossRefPubMed
38.
Latz D, Nassar N, Frank R. Trofosfamide in the palliative treatment of cancer: a review of the literature. Onkologie. 2004;27:572–6.PubMed
39.
Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–90.CrossRefPubMedCentralPubMed
40.
A predictive model for aggressive non-Hodgkin's lymphoma. The international non-Hodgkin's lymphoma prognostic factors project. N Engl J Med. 1993;329:987–94.CrossRef
41.
Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M, et al. Report of the committee on Hodgkin’s disease staging classification. Cancer Res. 1971;31:1860–1.PubMed
42.
Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579–86.CrossRefPubMed
43.
Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the eastern cooperative oncology group. Am J Clin Oncol. 1982;5:649–55.CrossRefPubMed
44.
Hoelzer D, Ludwig WD, Thiel E, Gassmann W, Löffler H, Fonatsch C, et al. Improved outcome in adult B-cell acute lymphoblastic leukemia. Blood. 1996;87(2):495–508.PubMed
45.
Chiappella A, Castellino A, Nicolosi M, Santambrogio E, Vitolo U. Diffuse large B-cell lymphoma in the elderly: standard treatment and new perspectives. Expert Rev Hematol. 2017;10(4):289–97.CrossRefPubMed
46.
Laribi K, Denizon N, Bolle D. R-CVP regimen is active in frail elderly patients aged 80 or over with diffuse large B cell lymphoma. Ann Hematol. 2016;95(10):1705–14.CrossRefPubMed
47.
Park SI, Grover NS, Olajide O, Asch AS, Wall JG, Richards KL, et al. A phase II trial of bendamustine in combination with rituximab in older patients with previously untreated diffuse large B-cell lymphoma. Br J Haematol. 2016;175(2):281–9.CrossRefPubMedCentralPubMed
48.
Weidmann E, Neumann A, Fauth F, Atmaca A, Al-Batran SE, Pauligk C, et al. Phase II study of bendamustine in combination with rituximab as first-line treatment in patients 80 years or older with aggressive B-cell lymphomas. Ann Oncol. 2011;22:1839–44.CrossRefPubMed
49.
Walter E, Schmitt T, Dietrich S, Ho A, Witzens-Harig M. Rituximab and bendamustine in patients with CD20+ diffuse large B-cell lymphoma not eligible for cyclophosphamide, doxorubicin, vincristine and prednisone-like chemotherapy. Leuk Lymphoma. 2012;53:2290–2.CrossRefPubMed
Metadata
Title
Low-dose trofosfamide plus rituximab is an effective and safe treatment for diffuse large B-cell lymphoma of the elderly: a single center experience
Authors
Roland Christian Schelker
Wolfgang Herr
Albrecht Reichle
Martin Vogelhuber
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2018
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-018-4885-5

Other articles of this Issue 1/2018

BMC Cancer 1/2018 Go to the issue

Research article

CRABP1, C1QL1 and LCN2 are biomarkers of differentiated thyroid carcinoma, and predict extrathyroidal extension

Research article

Health seeking behavior and its determinants for cervical cancer among women of childbearing age in Hossana Town, Hadiya zone, Southern Ethiopia: community based cross sectional study

Research article

PEST-containing nuclear protein mediates the proliferation, migration, and invasion of human neuroblastoma cells through MAPK and PI3K/AKT/mTOR signaling pathways

Research article

Positive expression of Midkine predicts early recurrence and poor prognosis of initially resectable combined hepatocellular cholangiocarcinoma

Research article

Metabolic control of PPAR activity by aldehyde dehydrogenase regulates invasive cell behavior and predicts survival in hepatocellular and renal clear cell carcinoma

Research article

Genomic alterations in gastric cancers discovered via whole-exome sequencing
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits